oxaliplatin Pt(IV) prodrug/texaphyrin (OxaliTEX) / OncoTEX - LARVOL DELTA

Profiling the Preclinical Pharmacokinetics and Biodistribution of a Platinum(IV)-Based Oxaliplatin Prodrug OxaliTEX and Their Significance to Antitumor Response. (PubMed, Mol Pharm) - "OxaliTEX (NOVO-111) is a novel gadolinium(III) texaphyrin-platinum(IV) complex that is under development for clinical trials. This suggests that other factors, such as the slow plasma terminal phase of the free Pt(II) species from oxaliTEX that prolongs exposure to low drug concentrations, may contribute to the favorable in vivo antitumor activity and therapeutic index of the conjugate. These characteristics demonstrate superiority of oxaliTEX and generate much optimism for its success in future clinical trials."

Journal • PK/PD data • Preclinical • Oncology • KRAS

OncoTEX Receives Notice of Allowance for Patent in Korea Regarding Ovarian Cancer-Fighting Drug OxaliTEX (GlobeNewswire) - "OncoTEX Inc....announced its novel cancer-fighting drug candidate, OxaliTEX, has received a notice of allowance for patent in Korea. This notice will further broaden OxaliTEX’s global protection and strengthen its intellectual property portfolio. The OxaliTEX Patent Cooperation Treaty (PCT) application was first published in 2015 and has since been granted patent protection in the U.S., Australia, Singapore, Mexico, and Israel."

Patent • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

OncoTEX Issued New U.S. Patent for Ovarian Cancer-Fighting Drug OxaliTEX (GlobeNewswire) - "OncoTEX Inc...announced its novel cancer-fighting drug candidate, OxaliTEX, has been issued a new U.S. patent....The new patent is a continuation of the oncology company’s 2019 issuance and will broaden OxaliTEX’s claims in the U.S. and strengthen its intellectual property portfolio."

Patent • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor